[go: up one dir, main page]

JOP20200035A1 - تركيبات حمض أميني لعلاج الإصابات العصبية - Google Patents

تركيبات حمض أميني لعلاج الإصابات العصبية

Info

Publication number
JOP20200035A1
JOP20200035A1 JOP/2020/0035A JOP20200035A JOP20200035A1 JO P20200035 A1 JOP20200035 A1 JO P20200035A1 JO P20200035 A JOP20200035 A JO P20200035A JO P20200035 A1 JOP20200035 A1 JO P20200035A1
Authority
JO
Jordan
Prior art keywords
treatment
amino acid
neuronal injury
acid compositions
injury
Prior art date
Application number
JOP/2020/0035A
Other languages
English (en)
Inventor
Raffi Afeyan
Sean Carroll
Rienzo Gianluca De
Matthew Russell
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of JOP20200035A1 publication Critical patent/JOP20200035A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0626—Isoleucine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0628—Leucine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0634—N-Acetyl-Cysteine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0654—Valine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds
    • A23V2250/306—Creatine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير تركيبات وطرق لعلاج أو منع الإصابة العصبية لدى خاضع، على سبيل المثال، خاضع معرض لخطر الإصابة الدماغية الرضحية أو السكتة الدماغية. الشكل 1
JOP/2020/0035A 2017-08-14 2018-08-14 تركيبات حمض أميني لعلاج الإصابات العصبية JOP20200035A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762545364P 2017-08-14 2017-08-14
US201862614198P 2018-01-05 2018-01-05
US201862697690P 2018-07-13 2018-07-13
PCT/US2018/046659 WO2019036442A1 (en) 2017-08-14 2018-08-14 AMINO ACIDS BRANCHED FOR THE TREATMENT OF NEURONAL INJURY

Publications (1)

Publication Number Publication Date
JOP20200035A1 true JOP20200035A1 (ar) 2020-02-13

Family

ID=63449701

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0035A JOP20200035A1 (ar) 2017-08-14 2018-08-14 تركيبات حمض أميني لعلاج الإصابات العصبية

Country Status (18)

Country Link
US (1) US20190046486A1 (ar)
EP (1) EP3684350A1 (ar)
JP (2) JP7370960B2 (ar)
KR (1) KR20200040276A (ar)
CN (1) CN111295186A (ar)
AU (1) AU2018318091A1 (ar)
BR (1) BR112020002244A2 (ar)
CA (1) CA3072092A1 (ar)
CL (1) CL2020000383A1 (ar)
CO (1) CO2020001627A2 (ar)
IL (1) IL272336A (ar)
JO (1) JOP20200035A1 (ar)
MA (1) MA50155A (ar)
MX (1) MX2020001766A (ar)
PE (1) PE20200748A1 (ar)
SG (1) SG11202001131TA (ar)
TW (1) TW201919602A (ar)
WO (1) WO2019036442A1 (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP2020517703A (ja) 2017-04-28 2020-06-18 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． アミノ酸組成物及び外傷性脳損傷の治療のためのそれらの使用
BR112020002244A2 (pt) * 2017-08-14 2020-08-04 Axcella Health Inc. aminoácidos de cadeia ramificada para o tratamento de lesão neurológica
CU20200012A7 (es) 2017-08-14 2021-02-04 Axcella Health Inc Composiciones de aminoácidos para el tratamiento de enfermedad hepática
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
CN112823018A (zh) 2018-06-20 2021-05-18 胺细拉健康公司 制备氨基酸组合物的方法
MA52971A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Compositions et procédés pour le traitement de l'infiltration de graisse dans le muscle
PT3934637T (pt) * 2019-03-02 2024-08-30 Intrabio Ltd (n-)acetil-l-leucina para utilização no tratamento de lesão cerebral traumática
IL300416A (en) * 2020-08-06 2023-04-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Oleylcysteine amide or its derivatives and their uses
US20220218640A1 (en) * 2021-01-14 2022-07-14 Rob Dickerman Amino acid delivery system
US11931127B1 (en) * 2021-04-08 2024-03-19 T-Mobile Usa, Inc. Monitoring users biological indicators using a 5G telecommunication network
EP4376826A1 (en) 2021-07-26 2024-06-05 Axcella (Assignment for the benefit of Creditors), LLC Amino acid compositions and methods for use in the treatment of post-acute sequelae of covid-19
WO2024243004A2 (en) * 2023-05-19 2024-11-28 The Children's Hospital Of Philadelphia Compositions and methods for treating traumatic brain injury
US20250099382A1 (en) * 2023-09-26 2025-03-27 Robert Austin Chittenden Colloidal suspension of nutraceutical ingredients to treat traumatic brain injury
CN119235838A (zh) * 2024-11-04 2025-01-03 苏州市立医院 一种hmb在制备改善创伤性脑损伤药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438144A (en) * 1980-07-31 1984-03-20 Blackburn George L Amino acid preparation and therapy for treatment of stress and injury
US20050107338A1 (en) * 2003-11-17 2005-05-19 Seidman Michael D. Nutritional supplement enhancing mitochondrial function
EP1863472B1 (en) * 2005-03-21 2013-02-20 Abbott Laboratories Amino acid composition for improving glucose tolerance
CN101693740B (zh) * 2009-10-16 2011-09-07 中国人民解放军第四军医大学 Homer1蛋白及其在治疗或预防脑损伤疾病中的应用
ES2893825T3 (es) * 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
US20130090356A1 (en) * 2011-06-24 2013-04-11 Jon D. Kaiser Compositions and methods for treatment of neuropsychological deficits
CA2799127C (en) * 2012-12-18 2021-05-18 Matthew Bennett Compositions and methods for treating traumatic brain injury
ES2844199T3 (es) * 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
CN106361738A (zh) * 2016-08-25 2017-02-01 南通大学 治疗、预防脑白质损伤的医药组合物及其医药用途
US20180133185A1 (en) * 2016-11-11 2018-05-17 The Children's Hospital Of Philadelphia Compositions and Methods for the Improvement of Memory
JOP20190147A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
JOP20190146A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
BR112020002244A2 (pt) * 2017-08-14 2020-08-04 Axcella Health Inc. aminoácidos de cadeia ramificada para o tratamento de lesão neurológica

Also Published As

Publication number Publication date
JP2020530843A (ja) 2020-10-29
SG11202001131TA (en) 2020-03-30
JP7370960B2 (ja) 2023-10-30
CO2020001627A2 (es) 2020-06-09
AU2018318091A1 (en) 2020-02-13
BR112020002244A2 (pt) 2020-08-04
PE20200748A1 (es) 2020-07-24
KR20200040276A (ko) 2020-04-17
IL272336A (en) 2020-03-31
CN111295186A (zh) 2020-06-16
CA3072092A1 (en) 2019-02-21
MA50155A (fr) 2020-07-29
MX2020001766A (es) 2020-07-29
EP3684350A1 (en) 2020-07-29
JP2023145496A (ja) 2023-10-11
WO2019036442A1 (en) 2019-02-21
WO2019036442A9 (en) 2020-02-13
AU2018318091A8 (en) 2020-03-12
TW201919602A (zh) 2019-06-01
US20190046486A1 (en) 2019-02-14
CL2020000383A1 (es) 2020-08-28

Similar Documents

Publication Publication Date Title
JOP20200035A1 (ar) تركيبات حمض أميني لعلاج الإصابات العصبية
SA519400950B1 (ar) Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة
JOP20200033A1 (ar) تركيبات حمض أميني لمعالجة مرض كبدي
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
WO2016070051A3 (en) Combination therapy for treatment of disease
MX2024008963A (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
SG10201908697XA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
WO2016113357A8 (en) Proteasome inhibitors for treating a disorder related to an accumulation of non-degraded abnormal protein or a cancer
WO2017007941A3 (en) Compositions and methods for identification, assessment prevention, and treatment of cancer using slncr isoforms
WO2017139570A8 (en) Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine
WO2017106364A3 (en) Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
MX2017000094A (es) PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS.
IL277182A (en) Compositions and methods for treating Parkinson's disease
MY187945A (en) Improved mouthwash preparation
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
ZA202101362B (en) Compositions and methods for treating the eye
WO2017040666A3 (en) Combination therapy for treatment of disease
MY208313A (en) Compositions and methods for treating brain injury
ZA202101342B (en) Compositions and methods for treating the eye
IL283654A (en) Decarboxylase inhibitors for the treatment of Parkinson's disease
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
ZA202007183B (en) Compositions and methods for treating the eye
ZA202101360B (en) Compositions and methods for treating the eye
ZA202101361B (en) Compositions and methods for treating the eye